{"id":"NCT00604214","sponsor":"Eli Lilly and Company","briefTitle":"Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2011-09","completion":"2012-02","firstPosted":"2008-01-30","resultsPosted":"2012-09-18","lastUpdate":"2012-09-18"},"enrollment":1696,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sepsis"],"interventions":[{"type":"DRUG","name":"Drotrecogin alfa (activated)","otherNames":["LY203638","Xigris"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Drotrecogin alfa (activated)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients receiving the current standard of care for septic shock. This study will also assess the effectiveness of drotrecogin alfa (activated) in reducing 28-day mortality in patients with septic shock and concomitant severe protein C deficiency.","primaryOutcome":{"measure":"28-Day All-Cause Mortality","timeFrame":"Day 28","effectByArm":[{"arm":"Drotrecogin Alfa (Activated)","deltaMin":26.4,"sd":null},{"arm":"Placebo","deltaMin":24.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.313"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":150,"countries":["United States","Australia","Belgium","Brazil","Canada","Czechia","Finland","France","Germany","India","Italy","Mexico","Netherlands","New Zealand","Portugal","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["25928214","22616830"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":119,"n":833},"commonTop":["Thrombocytopenia","Haematuria","Deep vein thrombosis","Atrial fibrillation","Catheter site haemorrhage"]}}